# SRPT — Sarepta Therapeutics · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SRPT  
**Sources:** 30  
**Published:** 2026-10-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-srpt-sarepta-therapeutics-catalysts-narrative-risks-9819

---

# Sarepta Therapeutics (SRPT) — Point-in-Time Research Summary (as of 2026-10-28)

## Valuation Snapshot

As of the latest prints on October 27–28, 2026, SRPT traded near ~$19–20, with a market capitalization of roughly $1.9B–$2.0B, and a 52-week range of approximately $14.68–$24.68 [[17]](https://tickernerd.com/stock/srpt-forecast/), [[26]](https://finance.yahoo.com/quote/SRPT/), [[27]](https://stockanalysis.com/stocks/srpt/). The stock is down roughly 12.2% year-to-date and about 19.6% over the past year, sitting roughly mid-range on its 52-week band [[17]](https://tickernerd.com/stock/srpt-forecast/), [[26]](https://finance.yahoo.com/quote/SRPT/), [[27]](https://stockanalysis.com/stocks/srpt/). It is not part of a major index such as the S&P 500 [[8]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/sarepta-therapeutics-stock-gains-analyst-support-after-mixed-rating-signals/70139108).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-srpt-sarepta-therapeutics-catalysts-narrative-risks-9819 (free to sign up)._
